This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Approves Competing Lung Disease Drugs From Roche and Boehringer

10/15/14 - 04:07 PM EDT

FDA Approves Competing Lung Disease Drugs From Roche and Boehringer U.S. patients suffering from idiopathic pulmonary fibrosis finally gain access to Esbriet, approved for use in Europe since early 2011.

READ FULL POST

Gilead Sciences Falls Amid Worries Over Hep-C Drug Price

10/14/14 - 10:53 AM EDT

Gilead Sciences Falls Amid Worries Over Hep-C Drug Price It's one thing for small-cap biotech stocks to trade horribly, but healthcare investors take notice when shares of Gilead Sciences GILD take a turn south.

READ FULL POST

Blame Arrowhead Management Entirely for Today's Epic Collapse

10/08/14 - 03:52 PM EDT

Blame Arrowhead Management Entirely for Today's Epic Collapse CEOs of early stage biotech companies like Arrowhead cannot deliver nasty surprises to Wall Street, yet some inexplicable reason, Anzalone totally botched the job.

READ FULL POST

The Disgusting Reaction to Ebola Patient's Death by Tekmira, Chimerix Traders

10/08/14 - 11:33 AM EDT

The Disgusting Reaction to Ebola Patient's Death by Tekmira, Chimerix Traders Tekmira shares surge after Thomas Duncan's death announced.

READ FULL POST

Arrowhead Research Sinks on Disappointing Hepatitis B Drug Data

10/08/14 - 10:38 AM EDT

Arrowhead Research Sinks on Disappointing Hepatitis B Drug Data In an ongoing phase II study, ARC-520 dosed at 2 mg/kg induced a 0.3 log reduction in HBsAG, a measure of the presence of hepatitis B virus in the body.

READ FULL POST

It's True, Small-Cap Biotech Stocks Are Acting Badly These Days

10/07/14 - 11:39 AM EDT

It's True, Small-Cap Biotech Stocks Are Acting Badly These Days For the past three months, small-cap biotech stocks have been underperforming the broader market.

READ FULL POST

Shkreli's Inability to Focus, Immaturity Cost Him Retrophin CEO Job

09/30/14 - 05:53 PM EDT

Shkreli's Inability to Focus, Immaturity Cost Him Retrophin CEO Job Martin is super smart and will be a great asset somewhere, but he is not a CEO. I wish him the best.

READ FULL POST

Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax

09/30/14 - 09:49 AM EDT

Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?

READ FULL POST

Clovis Shares Higher on Improved Outlook for Lung Cancer Drug

09/29/14 - 12:17 PM EDT

Clovis Shares Higher on Improved Outlook for Lung Cancer Drug Clovis Oncology shares are higher Monday because AstraZeneca, its direct competitor to develop a new, genetically targeted lung cancer drug, slipped this weekend.

READ FULL POST

Gilead Sciences' Next-Generation HIV Drug Hits the Mark

09/24/14 - 10:30 AM EDT

Gilead Sciences' Next-Generation HIV Drug Hits the Mark TAF is an improved version of Gilead's stalwart but patent challenged HIV drug Viread.

READ FULL POST

Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Upside.com. Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Adam's Tweets

Top Rated Stocks Top Rated Funds Top Rated ETFs